Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myriad Genetics, Inc. (MYGN) -- Ignore unavailable to you. Want to Upgrade?

To: flanew who wrote (22)	9/3/1998 10:54:00 PM
From: A.J. Mullen	Read Replies (1) \| Respond to of 2355

Today's recommendation that Tamoxifen be approved as a prophylactive for women at risk seems to me very bullish for MYGN. This was a controversial recommendation because Tamoxifen is itself carcinogenic. High-risk wasn't defined in any report I saw, but previously it has been described as those with a family history of the disease. I think it would be irresponsible to for this alone: an attempt should be made to confirm the risk with genetic testing. I doubled the number of shares I held today. This is a copy of the message I posted on the MYGN thread. It is crazy to have two. MYGN has more info in the header, so I suggest we all use that one.